Novartis

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

Retrieved on: 
Thursday, March 28, 2024
AbbVie, Inflammation, Growth, AstraZeneca, Astex Pharmaceuticals, Trinity College, Novartis, Patient, Research, Standard of care, University, Head, Trinity College Dublin, Therapy, Cancer, Drug development, Amgen, Marketing, Pharmaceutical industry

Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and strengthen the Board governance and oversight required for the next stage of the Company’s development and growth,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.

Key Points: 
  • Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and strengthen the Board governance and oversight required for the next stage of the Company’s development and growth,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
  • Dr. Gallagher has directly led or overseen multiple medical product approvals globally, including biologics and small molecules, across several therapeutic areas.
  • Before joining Syndax Pharmaceuticals in 2023, Dr. Gallagher was Head of Development and Chief Medical Officer of AbbVie.
  • Dr. Gallagher was also appointed to serve as a member of the research and development committee of the board of directors.

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Administration, EGFR, Mutation, Index, Colorectal cancer, Cetuximab, Central nervous system, Novartis, Webcast, Patient, GBM, CNS, Neoplasm, Acquisition, G&A, Insurance, BRAF, NRAS, MEK, CRC, Melanoma, ASCO, ID, MTD, Research and development, Probability, Data, FDA, Outsourcing, FTD, Pharmaceutical industry

SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter and full year ended December 31, 2023.

Key Points: 
  • In addition, a strategic pipeline prioritization sharpened Erasca’s focus on existing programs that we believe have the highest probability of success for patients.
  • Research and Development (R&D) Expenses: R&D expenses were $24.8 million for the quarter ended December 31, 2023, compared to $29.4 million for the quarter ended December 31, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses were $9.1 million for the quarter ended December 31, 2023, compared to $8.7 million for the quarter ended December 31, 2022.
  • Erasca will hold a conference call and webcast on Thursday, March 28, 2024 at 8:30 am ET.

Xencor Appoints Bart Cornelissen as Chief Financial Officer

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Hospitals, Genetics, Clinical Trials, Master of Science, Bill, Erasmus University Rotterdam, Pfizer, Rotterdam School, Novartis, Business administration, Acquisition, Cancer, Protein engineering, Biology, Investment, DSM (company), Malaria, Pharmaceutical industry

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer.
  • Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support.
  • “Bart’s exceptional track record in financial planning and analysis, business development and organizational excellence will be of great value to Xencor as we advance our maturing clinical-stage pipeline of drug candidates and continue to explore our XmAb® platforms against novel biology,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor.
  • He began his career within the life sciences and global health sectors at Novartis, in roles of increasing responsibility within global financial planning and analysis.

Deepening the Partnership: Dawn Health Introduces Ekiva for Enhanced Disease Management of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Retrieved on: 
Monday, April 8, 2024
Digital health, Disease, Caregiver, Partnership, Novartis, PNH, Patient, Conditional sentence, Multiple sclerosis, Paroxysmal nocturnal hemoglobinuria, Pharmaceutical industry

This latest Ekiva product launch signifies not only a continuation of the innovative and collaborative efforts between Dawn Health and Novartis, but also illustrates the customizability and efficiency of the modular Dawn platform.

Key Points: 
  • This latest Ekiva product launch signifies not only a continuation of the innovative and collaborative efforts between Dawn Health and Novartis, but also illustrates the customizability and efficiency of the modular Dawn platform.
  • Ekiva PNH is tailored to the specific needs of the PNH patient population, offering enhanced functionalities for supporting bespoke care and setting a new standard in patient personalization.
  • Ekiva addresses these challenges by providing a comprehensive digital platform that empowers a patient reducing the uncertainties associated with disease management.
  • With the launch of Ekiva PNH, Dawn Health and Novartis reaffirm their position at the forefront of digital innovation in healthcare, setting a new standard in the management of rare chronic diseases.

Deepening the Partnership: Dawn Health Introduces Ekiva for Enhanced Disease Management of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Retrieved on: 
Monday, April 8, 2024
Digital health, Disease, Caregiver, Partnership, Novartis, PNH, Patient, Conditional sentence, Multiple sclerosis, Paroxysmal nocturnal hemoglobinuria, Pharmaceutical industry

This latest Ekiva product launch signifies not only a continuation of the innovative and collaborative efforts between Dawn Health and Novartis, but also illustrates the customizability and efficiency of the modular Dawn platform.

Key Points: 
  • This latest Ekiva product launch signifies not only a continuation of the innovative and collaborative efforts between Dawn Health and Novartis, but also illustrates the customizability and efficiency of the modular Dawn platform.
  • Ekiva PNH is tailored to the specific needs of the PNH patient population, offering enhanced functionalities for supporting bespoke care and setting a new standard in patient personalization.
  • Ekiva addresses these challenges by providing a comprehensive digital platform that empowers a patient reducing the uncertainties associated with disease management.
  • With the launch of Ekiva PNH, Dawn Health and Novartis reaffirm their position at the forefront of digital innovation in healthcare, setting a new standard in the management of rare chronic diseases.

Orphan designation: Autologous CD34+ cells transduced with a lentiviral RNA vector that results in integrated cDNA encoding for functional cystinosin Treatment of cystinosis, 19/02/2021 Positive

Retrieved on: 
Tuesday, April 9, 2024
Community, Diagnosis, Civil service commission, Prevalence, Cell, Bone marrow, Disease, Novartis, Patient, Committee, RNA, Autotransplantation, EMA, IRIS, Cystinosis, Agency, European, COMP, Blood, European Commission, Marketing, Medicine, Pharmaceutical industry

All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.

Key Points: 
  • All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
  • The medicine, also known as AVR-RD-O4, is a gene therapy, produced from immature blood (stem) cells collected from the patient.
  • After infusion into the patient, these cells permanently settle in the bone marrow, where they multiply to produce mature blood cells.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

Retrieved on: 
Thursday, March 28, 2024
Novartis, Acute lymphoblastic leukemia, Head, LG, Translational research, Urology, Oncology, Drug discovery, Executive, LG Chem, Lung, Anschutz Medical Campus, Committee, SRL Diagnostics, University, Laboratory, Doctor of Philosophy, RWTH Aachen University, Senior, Radiopharmaceutical, European Medicines Agency, ARUP Laboratories, Therapy, Drug development, Pharmacology, Pharmaceutical industry

BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer. Dr. Braendle is a life sciences executive with experience spanning from early drug discovery to the launch of small molecules, biologics, radiopharmaceuticals, gene and cell therapies, and medical device development.

Key Points: 
  • BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer.
  • “We are delighted to have Dr. Braendle join the AVEO Oncology team particularly at this important juncture as we seek to become a global top 20 oncology leader,” said Michael P. Bailey, President and Chief Executive Officer of AVEO Oncology, an LG Chem company.
  • Today, AVEO Oncology, an LG Chem company, and LG Chem Life Sciences also announced the formation of its Scientific Advisory Committee (“Committee”).
  • The Scientific Advisory Committee is comprised of several leading cancer experts, including:
    Professor and Deputy Chair for Translational Research, Department of Gastrointestinal Medical Oncology
    University of Colorado Cancer Center, Aurora

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, March 20, 2024
Research, Employment, Plan, Novartis, Patient, Biostatistics, Microglia, Columbia University, University, Head, Senior, Drug, Therapy, Novartis Gene Therapies, Translational medicine, Bangladesh Technical Education Board, DSM-IV codes, Pharmaceutical industry

WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer.

Key Points: 
  • WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer.
  • "Dr. Kaufmann brings a wealth of experience that will be invaluable to the Vigil team,” said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil.
  • “As we further the development of both iluzanebart and VG-3927, we will benefit from her extensive background in neurological and rare diseases, as well as her proven expertise in both domestic and global drug development.”
    Dr. Kaufmann is an accomplished biotech executive joining Vigil Neuroscience from Affinia Therapeutics where she served as Chief Medical Officer leading medical, clinical, patient advocacy and regulatory strategy.
  • “I am honored and excited to join Vigil, a company at the forefront of developing innovative treatments for rare and common neurological diseases,” said Petra Kaufmann, M.D., M.S., F.A.A.N, Chief Medical Officer of Vigil.

BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

Retrieved on: 
Wednesday, March 20, 2024
Novartis, BNTX, Prostate cancer, Supervisory board, Survival, Science, BioNTech, COVID-19, Patient, Lung, Breast, Prostate, Cancer, Translation, Marketing, Development, Pharmaceutical industry

Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.

Key Points: 
  • Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.
  • Annemarie Hanekamp is a seasoned pharmaceutical executive experienced in developing patient-focused commercial strategies for innovative oncology products encompassing sales, marketing and market access.
  • I believe its COVID-19 vaccine will only be the beginning of a series of approved products to follow in the years to come,” said Annemarie Hanekamp, designated Chief Commercial Officer at BioNTech.
  • Annemarie Hanekamp is a Dutch citizen and holds degrees in biomedical sciences as well as organizational leadership.

FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director

Retrieved on: 
Wednesday, March 20, 2024
Medicines Discovery Catapult, Francis Crick Institute, AstraZeneca, Science, Drug discovery, Novartis, Fraunhofer, Patient, IPA, University, GE HealthCare, Biophysics, Fundamental, Investment, Pharmaceutical industry

Lorenz is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery, technology and innovation, business growth and financing strategy.

Key Points: 
  • Lorenz is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery, technology and innovation, business growth and financing strategy.
  • Lorenz has extensive global experience in pharmaceutical R&D, including positions as Vice President & Global Head at AstraZeneca and Executive Director at Novartis and Bayer Pharmaceuticals.
  • Keno Gutierrez, Chairman of the Board of FundaMental Pharma, commented: “We are excited to share that Lorenz, a seasoned and highly regarded industry leader, has joined our Board of Directors.
  • I am confident that Lorenz`s energy, conceptual guidance and reach will make a difference in advancing FundaMental Pharma`s key program to the next level.”